Stem Cells SpinWAR:SCS 25 Gross Margin % is 85.71% as of Mar. 2026, which is 7% below its 10-year median of 92.18. GuruFocus rates WAR:SCS with a GF Score™ of 25/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 732 Biotechnology companies, Stem Cells Spin ranks better than 62.3% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Stem Cells Spin had a gross margin of 85.71% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Stem Cells Spin Gross Margin % Related Terms
Stem Cells Spin Gross Margin % Historical Data
* Premium members only.
The historical data trend for Stem Cells Spin's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SCS vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Stem Cells Spin's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stem Cells Spin Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stem Cells Spin's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Stem Cells Spin's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Stem Cells Spin (WAR:SCS) has a Gross Margin % of 85.71% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Stem Cells Spin and its competitors. This is near median its historical median of 92.18. Over the past decade, Stem Cells Spin's Gross Margin % has ranged from 72.31 to 151.61. According to the industry distribution chart, Stem Cells Spin ranks #276 out of 732 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Stem Cells Spin's Gross Margin % too high?
Stem Cells Spin's current Gross Margin % of 85.71% is near median its 10-year median of 92.18. Over the past 10 years, this metric has ranged from a low of 72.31 to a high of 151.61. The Biotechnology industry median Gross Margin % is 60.91. Stem Cells Spin's value of 85.71% is 40.7% above this industry median. Based on the distribution chart, Stem Cells Spin ranks #276 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Stem Cells Spin has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #276 out of 732 companies for Gross Margin %. This puts Stem Cells Spin in the upper half of its industry. The industry median Gross Margin % is 60.91. Stem Cells Spin's value of 85.71% is 40.7% above this benchmark. Historically, Stem Cells Spin's own Gross Margin % has ranged from 72.31 to 151.61 over the past decade. While the company's 10-year median is 92.18 vs. the industry median of 60.91, Stem Cells Spin has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stem Cells Spin's current Gross Margin % of 85.71% is 40.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Stem Cells Spin and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Cells Spin's current Gross Margin % is 85.71%, which is near median its own 10-year median of 92.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.40 — trading 300% above its estimated fair value. The current Gross Margin % is 85.71%, which is near median its 10-year median of 92.18 and 40.7% above the Biotechnology industry median of 60.91. Stem Cells Spin's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current Gross Margin % is 85.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?
Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued.
The current stock price of zł0.40 is trading 300% above its estimated GF Value™ of zł0.10.
GuruFocus considers Stem Cells Spin to be Significantly Overvalued.
Key valuation signals for WAR:SCS:
Gross Margin %: 85.71% (near median its 10-year median of 92.18)
GF Value™: zł0.10 vs. price of zł0.40 (300% above fair value)
Industry Position: 40.7% above the Biotechnology median (#276 of 732)
No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
25GF Score
Get the complete analysis for WAR:SCS
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SCS has been successfully added to your 
